Literature DB >> 17019196

High-frequency oscillatory ventilation in infants and children.

Ana Lia Graciano1, Eugene B Freid.   

Abstract

The goal of mechanical ventilation in patients with acute lung injury is to support gas exchange and mitigate ventilator-associated lung injury. High-frequency oscillatory ventilation relies on the generation of a constant distending pressure, small tidal volumes and rapid respiratory rates with the intent to recruit atelectatic lung, reduce peak inflating pressures and limit volutrauma. The utilization of high-frequency oscillatory ventilation has dramatically increased in neonatal and pediatric intensive care units. As there is an overlap between the intensive care unit and the operating room, anesthesiologists must be familiar with recent advances in the care of infants and children with acute respiratory failure. High-frequency oscillatory ventilation has been used successfully to manage patients with severe respiratory failure who have failed conventional mechanical ventilation. When initiated early, high-frequency oscillatory ventilation has been shown to improve oxygenation and reduce acute and chronic lung injury in neonates, infants and children. Further trials are necessary to better delineate the benefits and risks of this therapy in various patient populations.

Entities:  

Year:  2002        PMID: 17019196     DOI: 10.1097/00001503-200204000-00004

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.706


  2 in total

1.  Computational simulation indicates that moderately high-frequency ventilation can allow safe reduction of tidal volumes and airway pressures in ARDS patients.

Authors:  Wenfei Wang; Anup Das; Oanna Cole; Marc Chikhani; Jonathan G Hardman; Declan G Bates
Journal:  Intensive Care Med Exp       Date:  2015-12-10

2.  Effective Tidal Volume for Normocapnia in Very-Low-Birth-Weight Infants Using High-Frequency Oscillatory Ventilation.

Authors:  Seul Mi Lee; Ran Namgung; Ho Sun Eun; Soon Min Lee; Min Soo Park; Kook In Park
Journal:  Yonsei Med J       Date:  2018-01       Impact factor: 2.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.